Please assess the completion status of the following clinical trial:

Trial Title: SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of either open-angle glaucoma or ocular hypertension;~* Must sign an informed consent form;~* Mean IOP measurements at both the Eligibility 1 and 2 visits, in at least 1 eye (the same eye\[s\]) ≥ 19 and \< 32 mmHg at 09:00.~* Willing and able to attend all study visits;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Women of childbearing potential who are pregnant, breast-feeding, intend to become pregnant during the study, or not using adequate birth control methods to prevent pregnancy throughout the study;~* Any form of glaucoma other than open-angle glaucoma or ocular hypertension;~* Ocular disease, trauma, infection, inflammation, pathology, or surgery as specified in the protocol;~* Any other conditions including severe illness which would make the subject, in the opinion of the Investigator, unsuitable for the study;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SIMBRINZA + PGA (Type: EXPERIMENTAL): Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
- Vehicle + PGA (Type: OTHER): Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days

Based on this trial design, predict the completion outcome and termination type (if applicable).